Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BIOLASE, INC (BIOL)
|
Add to portfolio |
|
|
|
| Price: |
$0.88
| | Metrics |
| OS: |
1.04
|
M
| |
-43
|
% ROE
|
| Market cap: |
$915.3
|
k
| |
-57
|
% ROIC
|
|
Net cash:
|
$17.5
|
M
| |
$16.80
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($17.1)
|
M
| |
|
|
|
EBIT
|
($20.3)
|
M
| |
|
|
| EPS |
($554.29)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 48.5 | 39.2 | 22.8 | 37.8 | 46.2 | 46.9 | 51.8 | 48.5 |
| Revenue growth | 23.7% | 72.0% | -39.7% | -18.1% | -1.6% | -9.4% | 6.9% | 1.7% |
| Cost of goods sold | 32.6 | 22.7 | 16.6 | 23.5 | 29.3 | 31.8 | 31.5 | 32.5 |
| Gross profit | 15.9 | 16.5 | 6.2 | 14.3 | 16.9 | 15.1 | 20.3 | 16.0 |
| Gross margin | 32.8% | 42.2% | 27.1% | 37.8% | 36.6% | 32.2% | 39.2% | 32.9% |
| Selling, general and administrative | -32.6 | | | | | | | |
| Sales and marketing | | 15.3 | 11.2 | 14.4 | 18.1 | 16.7 | 17.0 | 18.7 |
| Research and development | | | | | 5.2 | 6.2 | 7.8 | 7.3 |
| General and administrative | | | | | 11.8 | 9.7 | 10.5 | 10.3 |
| EBITA | -25.3 | -16.4 | -26.8 | -15.6 | -18.2 | -17.5 | -14.9 | -20.6 |
| EBITA margin | -52.3% | -41.9% | -117.5% | -41.3% | -39.4% | -37.4% | -28.8% | -42.5% |
| Amortization of intangibles | | | | | | | 0.1 | 0.1 |
| EBIT | -25.3 | -16.4 | -26.8 | -15.6 | -18.2 | -17.5 | -15.0 | -20.6 |
| EBIT margin | -52.3% | -41.9% | -117.5% | -41.3% | -39.4% | -37.4% | -28.9% | -42.6% |
| Pre-tax income | -28.5 | -16.1 | -16.7 | -17.9 | -21.5 | -17.4 | -15.2 | -20.1 |
| Income taxes | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | -0.6 | 0.2 | 0.2 |
| Tax rate | 0.0% | | | 0.2% | | 3.3% | | |
| Net income | -28.9 | -16.2 | -16.8 | -17.9 | -21.5 | -20.8 | -17.6 | -20.3 |
| Net margin | -59.5% | -41.2% | -73.9% | -47.2% | -46.6% | -44.4% | -33.9% | -41.8% |
| |
| Diluted EPS | ($4.16) | ($0.11) | ($0.56) | ($0.77) | ($1.05) | ($1.41) | ($1.45) | ($0.35) |
| Shares outstanding (diluted) | 6.9 | 146.9 | 30.1 | 23.2 | 20.6 | 14.8 | 12.1 | 58.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|